Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 642-362-8 | CAS number: 1190630-03-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction: other studies
Administrative data
- Endpoint:
- toxicity to reproduction: other studies
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- supporting study
- Study period:
- 1979
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment.
Data source
Referenceopen allclose all
- Reference Type:
- secondary source
- Title:
- No information
- Year:
- 2 004
- Bibliographic source:
- HSDB Hazardous Substances Data Bank, 2004 on line
- Reference Type:
- review article or handbook
- Title:
- Direct and indirect effects of docosanol (IK.2), the active principle in Tadenan, on the rat prostate
- Author:
- Muentzing J et al
- Bibliographic source:
- Invest. Urology 17(3):176-180
Materials and methods
- Principles of method if other than guideline:
- Type: other: Effects on the rat prostate
Method: other - GLP compliance:
- not specified
- Type of method:
- in vivo
Test material
- Reference substance name:
- Docosan-1-ol
- EC Number:
- 211-546-6
- EC Name:
- Docosan-1-ol
- Cas Number:
- 661-19-8
- Molecular formula:
- C22H46O
- IUPAC Name:
- docosan-1-ol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
Administration / exposure
- Route of administration:
- oral: gavage
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1, 10, 100 mg/kg
Basis:
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Duration of test: 29 days
Results and discussion
Any other information on results incl. tables
Docosanol administered by gavage to rats aged 6-7 months for 28 days did not affect bodyweight or the weights of any of the organs weighed other than a statistically significant increase in weight of the seminal vesicles at the lower dose levels (1 and 10 mg/kg/day). There were no histological differences in the accessory sexual organs.
The concentration of radioactive zinc was decreased at 1 and 10 mg/kg in the dorsolateral prostate and increased in muscle at 10 and 100 mg/kg. At 100 mg/kg RNA concentration of the ventral prostate was increased but RNA content remained unchanged. The DNA content and concentration was also unchanged, the quotient between the conentrations of RNA and DNA was increased at 100 mg/kg. Protein concentration was unchanged. Plasma LH was increased at 100 mg/kg while FSH and prolactin were unaffected.
In the older rats the weight of the dorsal prostate was decreased to 85% of the weight of controls by 1 mg/kg and the weight of the seminal vesicles increase to 125% at 10 mg/kg. Spleen weight was decreased to 80% by 1 and 100 mg/kg docosanol. The quotient between RNA and DNA concentration was increased (130%) in the ventral prostate at 100 mg/kg. There were no histopathological changes in the organs examined. Plasma testosterone was reduced at 100 mg/kg and prolactin cncentration at 1 or 10 mg/kg.
Orchidectomy resulted in a significant increase in weight of prostate, seminal vesicles and adrenals at 100 mg/kg docosanol but not at lower dose levels. The concentration of radioactive zinc was reduced in the dorsolateral prostate at 10 or 100 mg/kg.
Docosanol did not increase the prostrate weight in rats which had been both orchidectomised and adrenalectomised suggesting a role for the adrenals in stimulating the prostrate.
Studies in young rats suggested a thymolytic effec as 100 mg/kg docosanol reduced the weith of both thymus and splenn in intact animals.
Applicant's summary and conclusion
- Conclusions:
- Docosanol had no effect on the weight or histology of the prostate in intact rats but increased the RNA/DNA quotient in the ventral prostate. Plasma LH and testosterone were reduced. In orchidectomised rats docosanol increased the prostate and adrenal weight but there was no increase in orchidectomised adn adrenalectomised rats, a weight reduction being observed. Also docosanol had a thymolytic effect in intact rats but not in adrenalectomised rats where the thymus weight was increased. These results suggest a stimulation of adrenal steroid secretion but this may not be the only effect of docosanol.
This study was reported in the Hazardous Substances Data Bank, 2004
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.